SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : LASE (LaserSight Inc.) Seeing The Future
LASE 2.800+6.1%Dec 24 12:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (75)12/8/1999 3:13:00 PM
From: Sir Auric Goldfinger  Read Replies (2) of 93
 
LASE The recent FTC ruling was negative for VISX, BEAM and SNRS.This ruling is negative for LASE because any macro event that makes laser procedures more competitive, the less likely LASE will sell enough lasers to meet analysts' expectations.

NIDEK has a fuller complement of procedures, including myopia and coming out soon with astigmatism; in
addition, NIDEK has lasers to sell in inventory, while LASE does not.

Preferred Capital, a private placement agent for LASE, has reiterated its buy position.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News